Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (IST:GENIL)

Market Cap	38.66B +3.1%
Revenue (ttm)	19.18B -0.6%
Net Income	814.44M +318.5%
EPS	0.15 +251.2%
Shares Out	4.50B
PE Ratio	56.56
Forward PE	n/a
Dividend	0.05 (0.56%)
Ex-Dividend Date	Nov 12, 2025

Volume	477,096,827
Average Volume	44,749,667
Open	8.98
Previous Close	8.59
Day's Range	8.55 - 9.44
52-Week Range	7.12 - 14.93
Beta	-0.05
RSI	29.96
Earnings Date	May 15, 2026

About IST:GENIL

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. In addition, it manufactures, tra...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 682
• Stock Exchange: Istanbul Stock Exchange
• Ticker Symbol: GENIL

Financial Performance

In 2025, IST:GENIL's revenue was 19.18 billion, a decrease of -0.59% compared to the previous year's 19.29 billion. Earnings were 814.44 million, an increase of 318.50%.